Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint
In a move to expand its discovery enterprise, Charles River Laboratories $CRL has acquired KWS BioTest for £15 million (roughly $20 million) up front.
A provider of both in vivo and in vitro discovery services, KWS’ speciality spans immuno-oncology and inflammatory and infectious disease, allowing Charles River to further tap into the hot areas of oncology and immunology. The smaller company’s UK base also helps Charles River — headquartered in Wilmington, MA — reach that area.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
